Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients

Transplant Infectious Disease

Volumn 12, Issue 5, 2010, Pages 428-431

  Vigna, E ^a   De Vivo, A ^b   Gentile, M ^a   Morelli, R ^a   Lucia, E ^a   Mazzone, C ^a   Recchia, A G ^a   Vianelli, N ^b   Morabito, F ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Immunocompromise; Liposomal amphotericin B; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; IMMUNOCOMPROMISED PATIENT; LEISHMANIA; MALE; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED;

EID: 78650481172     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00519.x     Document Type: Article

References (29)

1. Bañuls AL, Hide M, Prugnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 2007; 64: 1-109.
2. World Health Organization. Division of Control of Tropical Diseases. Leishmaniasis control home page (updated 2009). Accessed May 20, 2010.
3. Basset D, Pratlong F, Ravel C, Puechberty J, Dereure J, Dedet JP. Les leishmanioses de'clare'es en France en 1999. BEH 2001; 5: 19-21.
4. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995; 73: 191-197.
5. Sereno D, Cavaleyra M, Zemzoumi K, Masquaire S, Ouaissi A, Lemesre JL. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 1998; 42: 3097-3102.
6. Thakur CP, Dedet JP, Narain S, Pratlong F. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans R Soc Trop Med Hyg 2001; 95: 187-189.
7. Berman JD, Edwards N, King M, Grogl M. Biochemistery of Pentostam resistant Leishmania. Trans R Soc Trop Med Hyg 1989; 40: 159-164.
8. Saenz RE, De Rodriguez CG, Johnson CM, Berman JD. Efficacy and toxicity of Pentostam against Panamanian mucosal leishmaniasis. Am J Trop Med Hyg 1991; 44: 394-398.
9. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344: 1599-1600.
10. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93: 319-323.
11. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 75-81.
12. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28: 42-48.
13. Dietze R, Fagundes SMS, Brito EF, et al. Treatment of kalaazar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89: 309-311.
14. Gaeta GB, Maisto A, Di Caprio D, et al. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J Infect Dis 2000; 32: 675-677.
15. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127: 133-137.
16. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8: 191-199.
17. Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34: 702-709.
18. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113: 934-940.
19. Veiga JPR, Wolff ER, Sampaio RN, Marsden PD. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet 1983; 3: 569.
20. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18: 83-90.
21. Gradoni L, Gramiccia M, Pettoello M, Di Martino L, Nocerino A. A new Leishmania infantum enzymatic variant, agent of an urban visceral case unresponsive to drugs. Trans R Soc Trop Med Hyg 1987; 81: 927-928.
22. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for chills and fever produced by infusing amphotericin B. J Infect Dis 1987; 156: 784-789.
23. Torre-Cisneros J, Villanueva JL. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus. Clin Infect Dis 1995; 20: 191.
24. Davidson RN, Di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22: 938-943.
25. Di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131: 271-277.
26. Berman JD. Editorial response: U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28: 49-51.
27. Di Martino L, Raimondi F, Scotti S, Davidson RN, Gradoni L, Giacchino R. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87: 477.
28. Smith OP, Hann IM, Cox H, Novelli V. Visceral leishmaniasis: rapid response to AmBisome treatment. Arch Dis Child 1995; 73: 157-159.
29. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 2009; 16: 599-614.